Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Conditions
Keywords
Biological Specimen Banks, Cancer, Gynecology
Brief summary
A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical datas to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to epithetial ovarian cancer, Fallopian tube cancer and Primitive peritoneal cancer.
Detailed description
A Clinical and Biological Database is a collection of reliable, prospective and representative datas. This collection, provided to the scientific community, will help to develope research programs such as : * Cinicals and biological predictive factors of treatments response * Identification of biological tumoral markers associate with survival * Identification of prognosic factors after recidivism * Diagnostics tests optimisation and follow-up from blood samples ( Circulating Tumor Cells (CTC) ) * Developing strong preclinical models. Those models would be later used to test alternative treatments and would help to identify new biomarkers
Interventions
OTHERBiological collection
* Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4) * Tissue samples (tumor tissue and healthy tissue) collected during the surgery
Sponsors
Institut du Cancer de Montpellier - Val d'Aurelle
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 or older * Patient at the diagnosis of an epithelial ovarian cancer, or a fallopian tube caner or a primitive peritoneal cancer * Patient eligible for, at least, one surgery and a chemotherapy * Patient having given his informed, written and express consent
Exclusion criteria
* Patient not affiliated to a social protection scheme * Pregnant and / or nursing women * Subject under tutelage, curatorship or safeguard of justice * Patient whose regular follow-up is impossible for psychological, familial, social or geographical reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients who gave their consent to participate in the study | Until the study completion : 3 years | The proportion of patients who consent to participate in the study among the screened patients |
Countries
France
Contacts
Primary ContactAurore MOUSSION
Outcome results
None listed